To Bring Cutting Edge BIO-Nano-Chip Lab Analysis Technology
From Prototype to Production
SensoDx, founded in mid-2014, is a pioneering medical micro-device company that specializes in the commercialization of powerful, yet affordable, chip-based diagnostic devices that are suitable for a broad range of essential clinical applications. SensoDx Provides OEM diagnostic solutions to strategic partners with established customer bases that are in need of a next generation diagnostics platform. SensoDx is uniquely placed amongst lab-on-a-chip technologies in terms of the advanced stage of its clinical validation. They are rapidly developing a broad menu of tests and service multiplexed and multiclass assays (cell counting, pathology and soluble biomarkers). Their current product line strategy is to yield large amounts of high performance and cost effective clinical data while retaining a tabletop form factor.
SensoDx was established around the award winning technology of Dr. John T. McDevitt, scientific founder and inventor of the programmable bio-nano-chip approach. For the past decade the group has been developing and perfecting a novel bead based assay system for biomarker based disease assessments. This platform technology dubbed the Programmable Bio-Nano-Chip (p-BNC) utilizes advanced biochemistry to provide a rapid and easy-to-use method for obtaining quantitative biomarker assessments for use at the point-of-care. By using the reagent minimization principles of microfluidics and a lab-on-a-chip form factor, the p-BNC assays provide a convenient way to monitor multiple biomarkers simultaneously, requiring significantly reduced amounts of chemical reagents, and can provide a biomarker diagnosis in minutes as compared to the week long wait-times of currently available lab-based tests.
This approach is suitable for broad range of testing modalities including protein, antibody, general chemistry, drug/metabolite, oligonucleotide, cell counting, and cytology assays.
The current SensoDx disease diagnostic portfolio encompasses cardiac heart disease, oral cancer, trauma, drugs of abuse, ovarian cancer and prostate cancer.
Dr. McDevitt said, ”The SensoDx partnership with XACTIV has been enormously productive and cost-effective, allowing our company to move more quickly toward the development of key instrumentation for our first product launch.” XACTIV is proud to be selected by SensoDx to help develop even more powerful and cost-effective instruments in the future in support of the SensoDx mission “to make this revolutionary technology broadly available for the good of mankind worldwide.”